A systematic review of the effectiveness of adalimumab
A systematic review of the effectiveness of adalimumab
A systematic review of the effectiveness of adalimumab
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
were not allowed, except in START. 105,111 Three<br />
trials (ASPIRE, 135 Taylor 140 and Quinn 141 )<br />
recruited exclusively early RA patients. Key<br />
features for studies that included <strong>the</strong> licensed dose<br />
<strong>of</strong> infliximab are described below.<br />
Maini and colleagues, 1998 137<br />
This 26-week, multicentre, double-blind RCT<br />
compared three doses <strong>of</strong> infliximab (1, 3 or<br />
10 mg kg –1 , with or without ongoing methotrexate<br />
7.5 per mg week) with placebo plus ongoing<br />
methotrexate. Patients who had taken<br />
methotrexate at a dose <strong>of</strong> 7.5–15 mg per week for<br />
at least 6 months, with at least six swollen joints<br />
were recruited. O<strong>the</strong>r DMARDs were not<br />
permitted. The primary efficacy measurement was<br />
<strong>the</strong> total time (in weeks) for which a patient<br />
exhibited a Paulus 20% response.<br />
© Queen’s Printer and Controller <strong>of</strong> HMSO 2006. All rights reserved.<br />
Health Technology Assessment 2006; Vol. 10: No. 42<br />
TABLE 10 Meta-analyses: etanercept s.c. licensed dose only (25 mg twice weekly or equivalent) versus placebo (with or without<br />
ongoing conventional DMARDs), end <strong>of</strong> trial<br />
Comparison or outcome Studies N included Statistical Effect size (95% CI)<br />
in analysis method<br />
ACR20 responder 7103,121,122,125,126,129,130 1172 RR (fixed) 3.59 (2.89 to 4.46)*<br />
ACR50 responder 7 103,121,122,125,126,129,130 1172 RR (fixed) 5.72 (3.92 to 8.34)*<br />
ACR70 responder 6 103,122,125,126,129,130<br />
1084 RR (fixed) 9.44 (3.98 to 22.38)*<br />
RD ACR20 responder 7 103,121,122,125,126,129,130 1172 RD (fixed) 0.48 (0.42 to 0.53)*<br />
RD ACR50 responder 7 103,121,122,125,126,129,130 1172 RD (fixed) 0.32 (0.28 to 0.37)*<br />
RD ACR70 responder 6 103,122,125,126,129,130<br />
1084 RD (fixed) 0.13 (0.10 to 0.16)*<br />
SJC, end <strong>of</strong> study result 7 103,121,122,125,126,129,130 1178 WMD<br />
(random)<br />
–6.75 (–8.95 to –4.56)*<br />
Patient’s global assessment, end <strong>of</strong> 7 103,121,122,125,126,129,130 study result<br />
1178 WMD (fixed) –2.49 (–2.74 to –2.24)*<br />
HAQ, end <strong>of</strong> study result 6 103,122,125,126,129,130<br />
1055 WMD (fixed) –0.50 (–0.59 to, –0.42)*<br />
DAS, end <strong>of</strong> study result 1 103<br />
150 WMD (fixed) –1.50 (–1.89 to –1.11)*<br />
Modified van de Heijde–Sharp score 0 0 Not estimable No data available<br />
Withdrawal for any reasons 7 103,104,121,122,125,126,129 1657 RR (fixed) 0.37 (0.29 to 0.46)*<br />
Withdrawal due to lack <strong>of</strong> efficacy 6 103,104,121,122,125,126<br />
1237 RR (fixed) 0.19 (0.13 to, 0.28)*<br />
Withdrawal due to adverse events 7 103,104,121,122,125,126,129 1657 RR (fixed) 0.80 (0.49 to 1.30)<br />
Death 7 103,104,121,122,125,126,129 1657 RR (fixed) 2.22 (0.50 to 9.80)<br />
SAEs 5 103,104,122,125,129<br />
1353 RR (fixed 1.25 (0.75 to 2.08)<br />
Malignancy: all 6 103,104,122,125,126,129<br />
1569 RR (fixed) 0.44 (0.11 to 1.68)<br />
Malignancy: skin cancer excluding 6 103,104,122,125,126,129<br />
melanoma<br />
1569 RR (fixed) 0.98 (0.17 to 5.59)<br />
Malignancy: all cancer excluding 6 103,104,122,125,126,129<br />
non-melanoma skin cancer<br />
1569 RR (fixed) 0.19 (0.02 to 1.71)<br />
Serious infection 7 103,104,122,125,126,129,130 1627 RR (fixed) 0.78 (0.37 to 1.62)<br />
Any infection 6 103,104,122,125,126,129<br />
1569 RR (fixed) 1.00 (0.87 to 1.14)<br />
* Statistically significant result (p < 0.05).<br />
ATTRACT: Maini and colleagues, 1999; 132<br />
Lipsky and colleagues, 2000 133<br />
This double-blind, multicentre RCT compared<br />
four dosing regimens <strong>of</strong> infliximab (3 or<br />
10 mg kg –1 , i.v. at 0, 2 and 6 weeks and <strong>the</strong>n every<br />
4 or 8 weeks) with placebo, with concomitant<br />
methotrexate <strong>the</strong>rapy. Patients who had been<br />
receiving methotrexate for at least 3 months and<br />
had been stable at 12.5 mg per week or more<br />
before screening were recruited. At least six<br />
swollen joints and six tender joints were required.<br />
The primary end-point was ACR20 response at<br />
week 30.<br />
The study was planned to run for 54 weeks, but it<br />
was extended by a protocol amendment to 102<br />
weeks based on FDA guidance. 134 A clinical study<br />
report for <strong>the</strong> 2-year results was provided by <strong>the</strong><br />
47